Search tips
Search criteria 


Logo of plosonePLoS OneView this ArticleSubmit to PLoSGet E-mail AlertsContact UsPublic Library of Science (PLoS)
PLoS One. 2008; 3(12): e3858.
Published online 2008 December 3. doi:  10.1371/journal.pone.0003858
PMCID: PMC2585477

GPRC6A Null Mice Exhibit Osteopenia, Feminization and Metabolic Syndrome

Jose A. L. Calbet, Editor



GPRC6A is a widely expressed orphan G-protein coupled receptor that senses extracellular amino acids, osteocalcin and divalent cations in vitro. The physiological functions of GPRC6A are unknown.

Methods/Principal Findings

In this study, we created and characterized the phenotype of GPRC6A −/− mice. We observed complex metabolic abnormalities in GPRC6A −/− mice involving multiple organ systems that express GPRC6A, including bone, kidney, testes, and liver. GPRC6A −/− mice exhibited hepatic steatosis, hyperglycemia, glucose intolerance, and insulin resistance. In addition, we observed high expression of GPRC6A in Leydig cells in the testis. Ablation of GPRC6A resulted in feminization of male GPRC6A −/− mice in association with decreased lean body mass, increased fat mass, increased circulating levels of estradiol, and reduced levels of testosterone. GPRC6A was also highly expressed in kidney proximal and distal tubules, and GPRC6A−/− mice exhibited increments in urine Ca/Cr and PO4/Cr ratios as well as low molecular weight proteinuria. Finally, GPRC6A −/− mice exhibited a decrease in bone mineral density (BMD) in association with impaired mineralization of bone.


GPRC6A−/− mice have a metabolic syndrome characterized by defective osteoblast-mediated bone mineralization, abnormal renal handling of calcium and phosphorus, fatty liver, glucose intolerance and disordered steroidogenesis. These findings suggest the overall function of GPRC6A may be to coordinate the anabolic responses of multiple tissues through the sensing of extracellular amino acids, osteocalcin and divalent cations.


GPRC6A is a recently identified member of family C of G protein-coupled receptors (GPCRs) that is most closely related to the calcium-sensing receptor CASR [1], [2], [3]. Structural homologies and conservation of specific domains in members of this family of receptors suggest an evolutionary link between extracellular calcium and amino acid-sensing [4], [5], [6]. Indeed, GPRC6A has recently been shown to sense extracellular cations and amino acids and to require both extracellular cations and amino acids for optimal stimulation in vitro [3]. This dual sensitivity of GPRC6A to both divalent cations and amino acids is analogous to the related receptor CASR [7]. Compared to CASR, much higher extracellular calcium concentrations are needed to activate GPRC6A [3], [8], and some studies suggest that cations may only be allosteric modulators of GPRC6A [9], whereas others show cation-dependent activation of GPRC6A [3]. The calcimimetic NPS-R578, an allosteric modulator of CASR [10], [11], [12], and osteocalcin, a bone derived calcium binding protein, both enhance the functional responses of GPRC6A to extracellular calcium in vitro [3]. The physiologically relevant ligands for and biological function of GPRC6A remain to be determined [13].

GPRC6A is broadly expressed in many tissues and organs, including lung, liver, spleen, heart, kidney, skeletal muscle, testis, brain and bone [1], [2], [3], [14]. The amino acid, osteocalcin, and divalent calcium ligand specificity of this receptor and its wide tissue distribution implicate GPRC6A multiple processes. For example, GPRC6A may be a candidate for the elusive extracellular calcium-sensing mechanism known to be present in osteoblasts [3], [15], [16], [17], [18], which respond to high local Ca2+ concentrations (in the range of 8 to 40 mM)[19], amino acids and osteocalcin in the bone microenvironment. GPRC6A is also a candidate for the putative osteocalcin receptor regulating energy metabolism [20]. To determine the function of GPRC6A, we created mice lacking this receptor. We found a complex multiorgan, metabolic-like syndrome in GPRC6A −/− mice that suggests that GPRC6A is involved in nutritional pathways coordinating the metabolic activity of multiple tissues in response to changes in extracellular amino acids and divalent cations.


Creation and Gross Phenotype of GPRC6A Deficient Mice

We selectively deleted exon 2 of the mouse GPRC6A gene (Fig. 1A). Wild-type GPRC6A +/+, heterozygous GPRC6A +/−, and homozygous GPRC6A −/− mice were genotyped by PCR (Fig. 1B) and each genotype was found to be born at the expected Mendelian frequencies from heterozygous breeding pairs, however, breeding pairs consisting of GPRC6A −/−×GPRC6A −/− had litter sizes that were roughly half that of GPRC6A −/−×GPRC6A+/+ or GPRC6A+/ and GPRC6A +/− breeding pairs, respectively (Data not shown). In addition, full-length GPRC6A transcripts and proteins were documented to be absent from various tissues of GPRC6A −/− mice by RT-PCR (Fig. 1C) and Western Blot (Fig. 1D). GPRC6A −/− mice (as well as heterozygous GPRC6A +/− mice) were similar in gross appearance, body weight and body length to wild-type littermates (data not shown). There were no identified abnormalities in gait or physical activity between wild-type and GPRC6A −/− mice.

Figure 1
Generation of GPRC6A knockout mice.

GPRC6A Deficiency is Associated with Testicular Feminization and Reduced Testosterone Levels

On closer inspection, we noted that male GPRC6A −/− mice had feminization of the external genitals (Figs. 2A–C). In 16-week-old male mice, the genito-anal distance (Figs. 2A and B) as well as testicular size (Fig. 2C), weight (Fig. 2D) and the weight of seminal vesicle (Fig. 2E) were significantly reduced in GPRC6A −/− compared to wild-type littermates. No histological abnormality of the testes was noted in GPRC6A −/− mice (Fig. 2F). GPRC6A was highly expressed in Leydig cells, and was also expressed in sertoli cells, spermatogonia and spermatids by in-situ hybridization analysis (Fig. 2F, lower panel). We also found abnormalities of mammary glands in male GPRC6A −/− mice, as evidence by greater ductal outgrowth in the mammary fat pad (in 10/14 GPRC6A −/− compared to 3/13 mice wild-type male mice) (Fig. 2G) and increased the mammary fat pad mass (Fig. 2H). We found no evidence of embryonic lethality or reduced fertility in homozygous null male or female mice when bred to their respective wild-type mates; however we observed a reduced litter size from breeding pairs consisting of both male and female homozygous null mice.

Figure 2
Characterization of reproductive system of male GPRC6A −/− mice.

Next, we compared the serum testosterone and estradiol concentration in 16-week-old mice wild-type and GPR6CA −/− mice. Testosterone concentrations in male GPRC6A knockout mice were significantly lower and the estradiol concentrations were significantly higher in male GPRC6A −/− mice compared to wild-type littermates (Table 1). Estradiol levels were not different between wild-type and GPRC6A −/− female mice, although the circulating testosterone levels were lower in female GPRC6A null mice (Data not shown).

Table 1
Serum and urinary biochemistries from GPRC6A+/+ and GPRC6A −/− mice at age of 16 week old.

Since inactivation of the androgen receptor is reported to lower testosterone levels in mice [21], [22], [23], we examined if loss of GPRC6A lowered androgen receptor expression. We observed no difference in the amount of AR transcripts in the testis and bone marrow by RT-PCR (Fig. 3A). Real-time RT-PCR also failed to demonstrate any difference in AR expression between GPRC6A null and wild-type mice (Fig. 3B). To explore the possibility that the reduction in testosterone was due to increased aromatase-mediated conversion for testosterone to estrogen, we examined aromatase gene (Cyp19a1) expression by real-time RT-PCR. The quantitative real-time PCR using primers located in exon 4 and the interface between exons 4 and 5 failed to document any difference in the expression of Cyp19a1 in GPRC6A null mice testis (Fig. 3C). We did, however, detect a small increase in aromatase (CPY19) protein levels in testis of GPRC6A −/− mice by Western Blot analysis (Fig. 3D) that was localized by immunhistochemistry (Fig. 3E) to Leydig cells, sertoli cells, and spermatocytes site where CPY19 is known to be expressed [24]. Aromatase protein level was slightly increased by approximately 11% in testis of GPRC6A −/− male mice (Fig. 3D). The significance of these changes in explaining the alterations in the testosterone and estradiol levels are uncertain, since we did not measure aromatase enzyme activity.

Figure 3
Possible mechanisms underlying altered testosterone/estrogen ratio in GPRC6A −/− male mice.

We found no reductions in the expression of P450 17α-hydroxylase gene (Cyp17), an enzyme that converts pregnenolone to dehydroandrosterone (DHEA) in the testosterone synthesis pathway [25], or estrogen sulfotransferase gene (EST/Sult1e1), which catalyzes the sulfoconjugation and inactivation of estrogens [26], in the GPRC6A −/− male mice testes by real-time PCR (Figs. 3G and H). Similarly, aromatase and Sult1e1 were not different in brain, fat, liver and pituitary of GPRC6A deficient and wild-type mice (data not shown). Furthermore, serum follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels in male mice were not significantly different between wild-type and the GPRC6A −/− male mice (Table 1). Gonadotrophin-releasing hormone gene (GnRH) message expression in the brain, however, was not altered in GPRC6A null mice (Figs. 3H and I).

Abnormalities in Renal Function in GPRC6A −/− mice

We previously demonstrated that GPRC6A is highly expressed in the kidney [3]. We extended these observations by showing that GPRC6A is expressed in both proximal and distal tubules by in situ hybridization (Fig. 4A). Interestingly, the expression of sodium-phosphate cotransporter, NaPi IIa, (both the protein (Fig. 4B) and transcript (Figs. 4C and D) was decreased ~50% in GPRC6A −/− mice, suggesting adaptive responses in the kidney to excrete phosphate. We also found that GPRC6A −/− mice had mild but significant increases in urinary calcium and phosphate excretion (calcium/creatinine ratio: 0.19±0.02; phosphorus/creatinine ratio: 5.32±0.31) compared to wild-type controls (calcium/creatinine ratio: 0.13±0.01; phosphorus/creatinine ratio: 3.93±0.28) (Table 1). The mild hypercalciuria was not evident at 6-weeks-of-age, but was present at subsequent ages, whereas the increased urinary phosphate levels were observed only in 16-week old GPRC6A −/− mice. The level of serum phosphorus was also significantly higher in 16 week-old knockout mice (6.52±0.18 mg/dl) compared to wild-type littermates (5.18±0.21 mg/dl) (Table 1). Circulating concentrations of calcium, PTH, FGF23, and 1,25(OH)2 vitamin D levels were not significantly different between wild-type and GPRC6A −/− mice (Table 1). In addition, we found that urinary protein excretion was elevated in GPRC6A −/− mice by Western blot analysis (Fig. 4E). Immunohistochemical analysis revealed that this protein band in the urine represents β2-microglobulin (Fig. 4F), providing evidence for abnormalities in the proximal tubule function in GPRC6A null mice.

Figure 4
GPRC6A deficiency is associated with a renal phenotype.

Metabolic Abnormalities in GPRC6A Deficient Mice

We also found that the liver of GPRC6A −/− mice exhibited histological features of hepatic steatosis by H&E and Oil Red O staining (Fig. 5A). Lipid positive droplets were present in hepatocytes of GPRC6A −/− mice but not wild-type mice. This correlated with increased triglyceride content in the livers of GPRC6A−/− mice (Fig 5B). In addition, we found that fasting serum glucose levels were significantly greater and insulin levels were lower in GPRC6A −/− mice compared to wild-type littermates (Table 1). Since fatty liver disease is a manifestation of “metabolic syndrome”, we examined GPRC6A −/− mice for evidence of glucose intolerance. We performed glucose tolerance tests following IP injection of glucose (2 g/kg of body weight) after an overnight fast (GTT), and insulin tolerance tests by IP injection of insulin (0.2 units/kg of body weight) after 6 hours fast (ITT). These tests revealed that GPRC6A −/− mice had a significantly higher serum glucose levels during the GTT and lower sensitivity to insulin than wild-type mice in the ITT (Fig. 5C and D, respectively).

Figure 5
GPRC6A deficiency is associated with a liver phenotype.

Musculoskeletal Phenotype of GPRC6A Deficient Mice

Both male and female GPRC6A −/− mice had a significant reduction in lean body mass compared to wild-type littermates (7.9% and 10% in male and 11.2% and 13% in female GPRC6A −/− mice at 12 and 16 weeks, respectively) as assessed by PIXImusTM densitometry (Fig. 6A). There were no apparent differences, however, in muscle histology between wild-type and GPRC6A −/− mice (data not shown). Body fat as assessed by PIXImusTM densitometry (Fig. 6B) and white fat by gross inspection of various organs, such as testis, were increased in GPRC6A −/− compared to wild-type mice. Both male and female GPRC6A −/− mice did not have the expected age-dependent increase in bone mineral density (BMD). Indeed, BMD was significantly less at 8, 12, and 16 weeks-of-age in GPRC6A −/− mice as compared to age-matched wild type mice (p<0.05) (Fig. 6C). To determine if the decreased bone density might be due to defective mineralization of bone, we performed backscatter EM and bone histological analysis. Backscatter EM of cortical bone demonstrated diminished mineralization surrounding osteocyte lacunae and on the perisoteal and endosteal surfaces (Fig. 6D). Qualitative analysis of bone histology also revealed an increase in unmineralized osteoid surfaces (Fig. 6E) and diffuse calcein labeling of bone compared to the distinct double labels in wild-type mice (Fig. 6F), indicative of impaired mineralization.

Figure 6
Characterization of the bone phenotype of GPRC6A −/− mice.


Recent data indicate that energy, fat, bone, and glucose metabolism are interrelated through novel hormonal regulatory pathways [20]. We observed a complex phenotype in GPRC6A −/− mice consisting of defective mineralization of bone and impaired osteoblast function in male and female mice, a decrease in lean body mass, an increase in fat mass, hyperphosphatemia and hypercalciuria, hyperglycemia and feminization of male mice associated with altered ratio of estradiol and testosterone, suggesting that GPRC6A participates in hormonal control of energy metabolism. Multiple organs and metabolic functions were affected by ablation of GPRC6A in mice.

Obesity-dependent metabolic syndrome is associated with impaired glucose tolerance and hepatic steatosis [27]. Similarly, GPRC6A −/− mice had elevated serum glucose levels (Table 1) glucose intolerance, insulin resistance and hepatic steatosis, as evidence by histological presence of fat and biochemical evidence of increase triglyceride content in livers of knockout mice (Fig. 5). The presence of a metabolic-like syndrome in GPRC6A −/− mice suggests that this receptor regulates metabolic pathways involved in glucose and fat metabolism, although these studies do not define the exact target organ of GPCR6A effects or whether this is a direct effect of GPRC6A or an indirect effect related to insulin resistance in GPRC6A −/− mice. Recently, osteocalcin produced by bone has been shown to be a circulating hormone that targets the pancreas to increase insulin secretion and adipocytes to increase adiponectin production [28]. Osteocalcin (Oc) has also been shown to target an unknown Gαi coupled GPCR [29] and can activate GPRC6A in the presence of extracellular calcium [3]. These observations raise the possibility that GPRC6A, might mediate some of the actions of Oc in vivo and provide a molecular pathway linking bone and energy metabolism. Future studies will be needed to determine if this receptor mediates the effects of osteocalcin on energy metabolism and to clarify the mechanisms underlying insulin resistance and hepatic steatosis in GPRC6A −/− mice.

Another phenotype was feminization of male GPRC6A −/− mice. Low testosterone levels acting observed in GPRC6A null mice, through classical genomic mechanisms, could explain the feminization of GPRC6A null mice. The phenotype of GPRC6A null mouse resembles, but is less severe than, the AR null and Tfm (Testicular feminized) mouse models [21], [23]. GPRC6A null mice, however, have inappropriately normal LH and FSH levels and increased estrogen, whereas the disruption of the genomic actions of AR is associated with increased LH and FSH and low estradiol levels [30]. Our studies do not define the mechanism of the altered testosterone/estrogen ratio. The alterations in circulating sex steroid levels in GPRC6A null mice might result from direct actions of the receptor to regulate testosterone biosynthesis or conversion to estrogens in the testis or other tissue, and/or to an indirect effect through potential GPRC6A regulation of the hypothalamus or pituitary gland. The observation that GPRC6A is expressed in the hypothalamus (GEO accession GDS565), gonadotrope cells of the anterior pituitary (GEO accession GDS2167), sertoli cells (GEO accession GDS222) and testes (GEO accession GDS2098) as well as the slight increase in level of aromatase protein expression in testis support both possibilities [2], [3], [14]. Testosterone replacement in GPRC6A −/− mice, measurement of aromatase activity and steroid biosynthesis, and assessment of GPRC6A function in other tissues will all be needed to establish the biological significance and mechanism of the observed reduction in testosterone levels in these mice.

The predominant effect of GPRC6A deficiency in bone was to impair bone mineralization. It is not clear whether these bone abnormalities represent a direct effect of GPRC6A loss from osteoblasts or secondary effects due to potential actions of the concomitant sex steroid hormone abnormalities on bone remodeling. But testosterone deficiency typically leads to increased osteoclast-mediated bone resorption [31], which was not observed in these animals. Further studies will be needed to determine the relative contribution of secondary alterations in sex hormones and primary loss of calcium-sensing receptor responses to the observed bone phenotype in GPRC6A null mice. Regardless, the expression of GPRC6A in bone and osteoblasts and the resulting bone phenotype raises the possibility that GPRC6A is a candidate for the novel osteoblastic calcium-sensing receptor [3], [15]. that is distinct from CASR [15].

With regard to the kidney, we observed that GPRC6A is expressed in both proximal and distal tubules and the ablation of this receptor resulted in increased renal excretion of calcium, phosphate, and β2-microglobulin. The effects of GPRC6A loss of function on urinary calcium excretion is opposite to the hypocalcuria caused by inactivating mutations of the related calcium sensing receptor CASR [32]. It is not clear from our studies if these renal abnormalities associated with disruption of GPRC6A function are direct or indirect. We failed to observe in GRPC6A null mice evidence of secondary increase PTH or increased bone turnover that would be expected if GPRC6A ablation resulted in a renal calcium leak. Theoretically, a primary decrease in bone formation and decreased buffering capacity for calcium, with consequent increased urinary expression of dietary calcium could account for the relationship between osteopenia and hypercalciuria in GPRC6A −/− mice. Alternatively, a primary effect of GPRC6A to regulate gastrointestinal phosphate transport would be another possible explanation for increased serum and urinary phosphate. There are some enigmatic clinical disorders with features similar to the GPRC6A −/− mice that support the possibility of coordinated effects between bone formation and renal conservation of calcium. In this regard, a subset of male patients with idiopathic osteoporosis and nephrolithiasis have the combined features of decreased osteoblast-mediated bone formation and hypercalciuria, without evidence of hypogonadism, secondary hyperparathyroidism, or abnormal vitamin D levels [33] [34]. It will be interesting to determine if gene polymorphisms of GPRC6A are associated with osteopenic and hypercalciuric clinical disorders. The observed reduction of NaPi IIa in GPRC6A −/− mice and the low molecular weight proteinuria is consistent with a primary proximal tubular defect. The increase in serum phosphate in GPRC6A −/− is unexplained.

In summary, we have shown that GPRC6A has multiple functions as evidenced by abnormalities in GPRC6A null mice that include alterations in circulating testosterone and estrogen levels and feminization of male mice, defects of bone density and bone cell function and abnormalities in the renal handling of calcium and phosphate, hyperglycemia and liver steatosis. The ligand profile of GPRC6A, which includes extracellular calcium, calcimimetics, amino acids, and osteocalcin [2], [3], [14], [20], along with the complex phenotype of GPRC6A null mice suggests that GPRC6A may represent an anabolic receptor that responds to a variety of nutritional and hormonal signals and may serve to coordinate the functions of multiple organs in response to changes of these ligands.

Materials and Methods

Generation of GPRC6A Knockout Mice

The GPRC6A-deficient mouse model was created by replacing exon 2 of the GPRC6A gene with the hygromycin resistance gene (Fig. 1). To generate the targeting construct, the hygromycin resistance gene under the control of the PGK promoter was cloned into the Sma I and Eco RV sites of pBS-lox, which was produced by cloning the oligonucleotide Lox71: 5′-ctagataccgttcgtatagcatacattatacgaagttatg-3′ into the Xba I and Bam HI sites and the oligonucleotide Lox 66: 5′-agcttataacttcgtatagcatacattatacgaacggtag-3′ into the Hind III and Sal I sites of pBluescript (Stratagene), to produce pBS-lox-PGK-Hyg. A genomic fragment from intron 1 of GPRC6A gene, representing the 5′ homologous targeting region, was amplified by PCR using Advantage 2 Taq polymerase (BD Biosciences) and primers PP 232-Avr: 5′-aaacctagggccattcatgaaaaaatgttgtcctcagatgaccatcc-3′, and PP 233-Avr: 5′-aaacctaggctcactcaacccccatgtccttccaactctagctg-3′, digested with Avr II, and cloned into the Xba I site of pBS-lox-PGK-Hyg to produce pBS-GPRC6A-Intron 1. A genomic fragment from intron 2 of GPRC6A, representing the 3′ homologous targeting region, was then amplified by PCR using Advantage 2 Taq polymerase and primers 298: 5′-aaagtcgacctacattggtccatcgattacattagttcttgg-3′ and PP 299: 5′-aaagtcgacgaggccttgaggtcaaactccagaaccccagag-3′, digested with Sal I, and cloned into the Sal I site of pBS-GPRC6A-Intron I to produce pGPRC6A-KO. The methods for knocking out the GPRC6A gene have been described previously in detail [35]. Briefly, the mouse embryonic cell line RW-4, derived from 129X1/SvJ mouse strain[36] and kindly provided by Stephan Teglund at the Karolinska Institute Center for Transgene Technologies, was transfected by electroporation with Not I linearized pGPRC6A-KO. Hygromycin resistant embryonic stem cell colonies were picked, expanded, and tested by PCR to identify clones in which the PGK-Hygromycin gene had correctly replaced exon 2 of the GPRC6A gene. The correctly mutated embryonic stem clones were injected into blastocysts derived from C57BL/6 3.5 days after mating and implanted into B6CBAF1 pseudopregnant females. The resulting male chimeras were bred with female C57BL/6 mice. Homozygous founders were generated by mating the resulting heterozygous mice. The successful targeting of GPRC6A in embryonic stem (ES) cells was confirmed by Southern blot analysis of the genomic DNA from ES cell clones. We observed no apparent differences in the founders generated from different ES cell clones. We focused our studies on founder line 17.

Mice were maintained and used in accordance with recommendations as described (National Research Council. 1985) Guide for the Care and Use of Laboratory Animals DHHS Publication NIH 86-23 , Institute on Laboratory Animal Resources, Rockville, MD) and following guidelines established by the University of Kansas Medical Center Institutional Animal Care and Use Committee.

PCR primers

The following intron-spanning primer sets were used for RT-PCR: mGPRC6A.24.For: ccagaaagatggccctattga; mGPRC6A.1754.Rev: ctccttactggggcccagtggg; mAndR.F578: caacttgcatgtggatgacc and mAndR.R961: cttgagcaggatgtgggattc. mGnRH.For169: agcactggtcctatgggttg and mGnRH.Rev389: gggccagtgcatctacatct. NaPiII.F248: ccacctatgccatctccagt and NaPiII.R635: accatgctgacaatgatgga; mALP.905F: aacccagacacaagcattcc and mALP.1458R: ctgggcctggtagttgttgt, G3PDH.F143: gaccccttcattgacctcaactaca; G3PDH.R1050: ggtcttactccttggaggccatgt for control RNA loading. The following primer sets were used for real-time PCR: aromatase forward primer: tgagaacggcatcatatttaacaac and reverse primer: gcccgtcagagctttcataaag; Cyp17 forward primer: tggaggccactatccgagaa and reverse primer: tgttagccttgtgtgggatgag; and Sult1e1 forward primer: tcatgcgaaagggaattatagga and reverse primer: tgcttgtagtgctcatcaaatctct.

RT-PCR and Real-Time RT-PCR

RT-PCR was performed using two-step RNA PCR (Perkin-Elmer) as previously described [3]. Specific intron-spanning primer sets were to amply the specified transcripts. For quantitative real-time RT-PCR assessment of bone markers expression, we isolated and reverse transcribed 2.0 µg total RNA from long bone of 8-week-old mice as previously described [37]. For quantitative real time RT-PCR assessment of aromatase, CYP17 and Sutl1e1 genes expression we isolated and reverse transcribed total RNA isolated from testis, brain, fat, liver and pituitary of 33 week-old GPRC6A+/+ (n = 5) and GPRC6A −/− mice (n = 5) as previously described [38] using specific primer sets. For expression of AR, GnRH and NaPi IIa, the oligo primers sequences were obtained from Primer Bank, a public resource for PCR primers ( [39], and the threshold cycle (Ct) of tested-gene product from the indicated genotype was normalized to the Ct for cyclophilin A as we have previously described [37].

Cell Culture and Western Blotting

HEK-293 cells were co-transfected with pcDNA3.mGPRC6A or pcDNA3 plasmid as previously described [3]. An anti-peptide antibody was raised in a rabbit against a peptide (AIHEKMLSSDDHPRRPQIQKC) corresponding to a sequence in the extracellular domain of mouse GPRC6A (in exon 1 of mouse GPRC6A gene) produced by Abgent (San Diego, CA). For phospho-ERK, the phospho-ERK1/2 levels were determined by immunoblotting using anti-phospho-ERK1/2 mitogen-activated protein kinase antibody (Cell Signaling Technology) [3]. Urinary β2-mcroglobulin was detected by rabbit polyclonal anti-β2-mcroglobulin antibody (Abcam Inc.). For aromatase expression analysis, the rabbit polyclonal anti-aromatase antibody (Abcam Inc.) and goat anti-rabbit IgG HRP secondary antibody (Santa Cruz Biotechnology Inc.) were used. Mouse anti-Actin antibody (Santa Cruz Biotechnology Inc.) was used for control protein loading.

PIXImus™ Bone Densitometer Analysis and Bone Histology

Bone mineral density (BMD) of whole skeletons and femurs were assessed at 6, 8, 12, and 16 weeks of age using a PIXImus™ bone densitometer (Lunar Corp.) as previously described [32]. Skeletons of mice were performed as reported previously by our laboratory [32].

Backscattered Scanning Electron Microscopy

Plastic embedded bone from 8 week-old wild-type and GPRC6A knockout mice were cut and polished, and mounted on aluminum sockets with bone surface facing above, sputter-coated with gold and palladium, and examined with field emission scanning electron microscopy (Philips XL30, FEI Company) equipped with a backscatter electron imaging system.


Wild-type and GPRC6A mouse kidney were routinely processed and embedded in paraffin. The paraffin sections at thickness of 5 µm were prepared and collected on commercially available, positively charged glass slides (Superfrost Plus, Fisher Scientific). The sections were dried on a hot plate to increase adherence to the slides. Representative sections were de-paraffined and re-hydrated through conventional methods. The sections were digested by 10 mg/ml hyaluronidase for 20 min. Nonspecific protein binding was blocked by incubation with 10% normal goat serum. The sections were incubated in polyclonal rabbit against mouse NaPi IIa (1[ratio]500 dilution) or polyclonal goat anti-human aromatase antibody (1[ratio]200 dilution) (CYP19, Santa Cruz Biotechnology, Inc.) at 4°C overnight. The negative control sections were incubated with 0.01 M PBS. Thereafter, the sections were treated sequentially with FITC-conjugated Donkey anti Rabbit IgG secondary antibody (Jackson Labs). The nucleus was stained with ready to use Hoechst (Sigma).

Whole-Mounts and Carmine Stain of Mammary Glands

Mice mammary fat pads were excised and fixed for a minimum of 2 h in Carnoy's solution (60% ethanol, 30% chloroform, and 10% glacial acetic acid). The fixed glands were washed in 70% ethanol for 15 min and then rinsed in water for 5 min. The mammary glands were stained overnight at 4°C in carmine alum stain (1 g carmine and 2.5 g aluminum potassium sulfate in 500 ml water).

In Situ Hybridization

For GPRC6A gene expression, the probe was amplified by RT-PCR using following intron spanning primer: mGPRC6A.189F (in Exon I) cgggat ccagacgaccacaaatccag and mGPRC6A.539R (spanned over Exon II and III) ccaagctt gattcataactcacctgtggc. After RT-PCR, the product was subclone into pre-cutted by BamH I and Hind III of pBluescript SK(+). Using T7 promoter will create sense RNA, and T3 promoter will create Anti-sense RNA ribo-probe.

Serum and Urine Biochemical Measurements

Serum was collected using a retroorbital bleeding technique. For urine samples collection, mice were placed in metabolic cages (Hatteras Instrument), and urine was collected for 24 h. The urine volume was measured before storage at −70°C.

Serum testosterone and estradiol levels were measured by testosterone enzyme immunoassay test kit and estradiol (E2) enzyme immunoassay test kit from BioCheck, Inc. Follicle stimulating hormone (FSH) and luteinizing hormone (LH) were measured by mouse FSH radioimmunoassay and the mouse LH sandwich assay as described by the University of Virginia Center for Research in Reproduction Ligand and Analysis Core (NICHD (SCCPRR) Grant U54-HD28934). Serum and urinary Calcium was measured by the colorimetric cresolphthalein binding method, and phosphorus was measured by the phosphomolybdate–ascorbic acid method [32]. Serum TRAP was assayed with the ELISA-based SBA Sciences mouseTRAP™ assay. Serum PTH and 1, 25 (OH)2 vitamin D were measured the kits from Immutopics, Inc. and Immunodiagnostic system, Ltd., respectively. Serum Fgf23 levels were measured by using FGF-23 ELISA kit (Kainos Laboratories Inc.) following the manufacturer's protocol. Creatinine was measured by the colorimetric alkaline picrate method (Sigma kit 555, Sigma-Aldrich). Urinary protein and Dpd were measured by Bio-Rad and Metra Biosystems, Inc., respectively.

Metabolic Studies

For glucose tolerance test (GTT) glucose (2 g/kg body weight) was injected intraperitoneally (IP) after an overnight fast, and blood glucose was monitored using blood glucose strips and the Accu-Check glucometer (Roche) at indicated times. For insulin tolerance test (ITT) mice were fasted for 6 hr, injected IP with insulin (0.2 U/kg body weight, Lilly Research Laboratories), and blood glucose levels were measured at indicated times as described [20]. ITT data are presented as percentage of initial blood glucose concentration.


We evaluated differences between groups by one-way analysis of variance. All values are expressed as mean±SEM. All computations were performed using the Statgraphic statistical graphics system (STSC Inc.).


Competing Interests: Athersys, Inc holds patient rights to drug development for GPRC6A in bone.

Funding: This work was supported by NIH R01-AR37308 (L. D. Q.) and COBRE grant P20 RR017686 (M. P.).


1. Wellendorph P, Brauner-Osborne H. Molecular cloning, expression, and sequence analysis of GPRC6A, a novel family C G-protein-coupled receptor. Gene. 2004;335:37–46. [PubMed]
2. Kuang D, Yao Y, Lam J, Tsushima RG, Hampson DR. Cloning and characterization of a Family C orphan G-protein coupled receptor. J Neurochem. 2005;93:383–391. [PubMed]
3. Pi M, Faber P, Ekema G, Jackson PD, Ting A, et al. Identification of a novel extracellular cation-sensing G-protein-coupled receptor. J Biol Chem. 2005;280:40201–40209. [PMC free article] [PubMed]
4. Folkers K, Bowers CY, Tang PF, Kubota M. Decapeptides as effective agonists from L-amino acids biologically equivalent to the luteinizing hormone-releasing hormone. Proc Natl Acad Sci U S A. 1986;83:1070–1074. [PubMed]
5. Conigrave AD, Quinn SJ, Brown EM. L-amino acid sensing by the extracellular Ca2+-sensing receptor. Proc Natl Acad Sci U S A. 2000;97:4814–4819. [PubMed]
6. Tabata T, Araishi K, Hashimoto K, Hashimotodani Y, van der Putten H, et al. Ca2+ activity at GABAB receptors constitutively promotes metabotropic glutamate signaling in the absence of GABA. Proc Natl Acad Sci U S A. 2004;101:16952–16957. [PubMed]
7. Tfelt-Hansen J, Brown EM. The calcium-sensing receptor in normal physiology and pathophysiology: a review. Crit Rev Clin Lab Sci. 2005;42:35–70. [PubMed]
8. Pi M, Quarles LD. A novel cation-sensing mechanism in osteoblasts is a molecular target for strontium. J Bone Miner Res. 2004;19:862–869. [PubMed]
9. Wellendorph P, Burhenne N, Christiansen B, Walter B, Schmale H, et al. The rat GPRC6A: Cloning and characterization. Gene 2007 [PubMed]
10. Hu J, Reyes-Cruz G, Chen W, Jacobson KA, Spiegel AM. Identification of acidic residues in the extracellular loops of the seven-transmembrane domain of the human Ca2+ receptor critical for response to Ca2+ and a positive allosteric modulator. J Biol Chem. 2002;277:46622–46631. [PMC free article] [PubMed]
11. Petrel C, Kessler A, Dauban P, Dodd RH, Rognan D, et al. Positive and negative allosteric modulators of the Ca2+-sensing receptor interact within overlapping but not identical binding sites in the transmembrane domain. J Biol Chem. 2004;279:18990–18997. [PubMed]
12. Miedlich SU, Gama L, Seuwen K, Wolf RM, Breitwieser GE. Homology modeling of the transmembrane domain of the human calcium sensing receptor and localization of an allosteric binding site. J Biol Chem. 2004;279:7254–7263. [PubMed]
13. Christiansen B, Hansen KB, Wellendorph P, Brauner-Osborne H. Pharmacological characterization of mouse GPRC6A, an L-alpha-amino-acid receptor modulated by divalent cations. Br J Pharmacol. 2007;150:798–807. [PMC free article] [PubMed]
14. Wellendorph P, Hansen KB, Balsgaard A, Greenwood JR, Egebjerg J, et al. Deorphanization of GPRC6A: a promiscuous L-alpha-amino acid receptor with preference for basic amino acids. Mol Pharmacol. 2005;67:589–597. [PubMed]
15. Pi M, Garner SC, Flannery P, Spurney RF, Quarles LD. Sensing of extracellular cations in CasR-deficient osteoblasts. Evidence for a novel cation-sensing mechanism. J Biol Chem. 2000;275:3256–3263. [PubMed]
16. Quarles LD, Gitelman HJ, Drezner MK. Induction of de novo bone formation in the beagle. A novel effect of aluminum. J Clin Invest. 1988;81:1056–1066. [PMC free article] [PubMed]
17. Martin TJ, Sims NA. Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol Med. 2005;11:76–81. [PubMed]
18. Zaidi M, Shankar VS, Tunwell R, Adebanjo OA, Mackrill J, et al. A ryanodine receptor-like molecule expressed in the osteoclast plasma membrane functions in extracellular Ca2+ sensing. J Clin Invest. 1995;96:1582–1590. [PMC free article] [PubMed]
19. Cohen A, Silverberg SJ. Calcimimetics: therapeutic potential in hyperparathyroidism. Curr Opin Pharmacol. 2002;2:734–739. [PubMed]
20. Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, et al. Endocrine regulation of energy metabolism by the skeleton. Cell. 2007;130:456–469. [PMC free article] [PubMed]
21. Gaspar ML, Meo T, Bourgarel P, Guenet JL, Tosi M. A single base deletion in the Tfm androgen receptor gene creates a short-lived messenger RNA that directs internal translation initiation. Proc Natl Acad Sci U S A. 1991;88:8606–8610. [PubMed]
22. He WW, Kumar MV, Tindall DJ. A frame-shift mutation in the androgen receptor gene causes complete androgen insensitivity in the testicular-feminized mouse. Nucleic Acids Res. 1991;19:2373–2378. [PMC free article] [PubMed]
23. Yeh S, Tsai MY, Xu Q, Mu XM, Lardy H, et al. Generation and characterization of androgen receptor knockout (ARKO) mice: an in vivo model for the study of androgen functions in selective tissues. Proc Natl Acad Sci U S A. 2002;99:13498–13503. [PubMed]
24. Carreau S, Lambard S, Delalande C, Denis-Galeraud I, Bilinska B, et al. Aromatase expression and role of estrogens in male gonad : a review. Reprod Biol Endocrinol. 2003;1:35. [PMC free article] [PubMed]
25. Auchus RJ. Overview of dehydroepiandrosterone biosynthesis. Semin Reprod Med. 2004;22:281–288. [PubMed]
26. Tong MH, Christenson LK, Song WC. Aberrant cholesterol transport and impaired steroidogenesis in Leydig cells lacking estrogen sulfotransferase. Endocrinology. 2004;145:2487–2497. [PubMed]
27. Perlemuter G, Bigorgne A, Cassard-Doulcier AM, Naveau S. Nonalcoholic fatty liver disease: from pathogenesis to patient care. Nat Clin Pract Endocrinol Metab. 2007;3:458–469. [PubMed]
28. Ferron M, Hinoi E, Karsenty G, Ducy P. Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc Natl Acad Sci U S A. 2008;105:5266–5270. [PubMed]
29. Bodine PV, Komm BS. Evidence that conditionally immortalized human osteoblasts express an osteocalcin receptor. Bone. 1999;25:535–543. [PubMed]
30. Ulloa-Aguirre A, Valdez E, Chavez B, Perez-Palacios G. [Biochemical and endocrine heterogeneity in the complete form of testicular feminization syndrome]. Gac Med Mex. 1990;126:297–304; discussion 304-296. [PubMed]
31. Reim NS, Breig B, Stahr K, Eberle J, Hoeflich A, et al. Cortical bone loss in androgen-deficient aged male rats is mainly caused by increased endocortical bone remodeling. J Bone Miner Res. 2008;23:694–704. [PubMed]
32. Tu Q, Pi M, Karsenty G, Simpson L, Liu S, et al. Rescue of the skeletal phenotype in CasR-deficient mice by transfer onto the Gcm2 null background. J Clin Invest. 2003;111:1029–1037. [PMC free article] [PubMed]
33. Zerwekh JE, Sakhaee K, Breslau NA, Gottschalk F, Pak CY. Impaired bone formation in male idiopathic osteoporosis: further reduction in the presence of concomitant hypercalciuria. Osteoporos Int. 1992;2:128–134. [PubMed]
34. Giannini S, Nobile M, Sella S, Dalle Carbonare L. Bone disease in primary hypercalciuria. Crit Rev Clin Lab Sci. 2005;42:229–248. [PubMed]
35. Svard J, Heby-Henricson K, Persson-Lek M, Rozell B, Lauth M, et al. Genetic elimination of Suppressor of fused reveals an essential repressor function in the mammalian Hedgehog signaling pathway. Dev Cell. 2006;10:187–197. [PubMed]
36. Hug BA, Wesselschmidt RL, Fiering S, Bender MA, Epner E, et al. Analysis of mice containing a targeted deletion of beta-globin locus control region 5′ hypersensitive site 3. Mol Cell Biol. 1996;16:2906–2912. [PMC free article] [PubMed]
37. Xiao ZS, Simpson LG, Quarles LD. IRES-dependent translational control of Cbfa1/Runx2 expression. J Cell Biochem. 2003;88:493–505. [PubMed]
38. Hiroi H, Christenson LK, Chang L, Sammel MD, Berger SL, et al. Temporal and spatial changes in transcription factor binding and histone modifications at the steroidogenic acute regulatory protein (stAR) locus associated with stAR transcription. Mol Endocrinol. 2004;18:791–806. [PubMed]
39. Wang X, Seed B. A PCR primer bank for quantitative gene expression analysis. Nucleic Acids Res. 2003;31:e154. [PMC free article] [PubMed]

Articles from PLoS ONE are provided here courtesy of Public Library of Science